Search Results - "Eremeeva, A. V."

Specificity of Teaching in the Section «General Epidemiology of Infectious Diseases» for Foreign Students by Tsvirkun, O. V., Eremeeva, A. V., Emerole, K. C., Polibin, R. V., Kogzevnikova, G. M.

“…Teaching the discipline «Epidemiology» to foreign students is associated with certain difficulties due to both the lack of equivalents in the English language…”
Get full text

Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR by Mazurov, V. I., Nasonov, E. L., Lila, A. M., Korolev, M. A., Prystrom, A. M., Kundzer, E. V., Soroka, N. F., Kastanayan, A. A., Povarova, T. V., Plaksina, T. V., Antipova, O. V., Krechikova, D. G., Smakotina, S. A., Tciupa, O. A., Puntus, E. V., Raskina, T. A., Shilova, L. N., Kropotina, T. V., Nesmeyanova, O. B., Popova, T. A., Vinogradova, I. B., Dokukina, E. A., Plotnikova, A. V., Pukhtinskaia, P. S., Zinkina-Orikhan, A. V., Linkova, Yu. N., Eremeeva, A. V., Lutckii, A. A.

“…—Background . Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active…”
Get full text

Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS by Boyko, A N, Alifirova, V M, Lukashevich, I G, Goncharova, Z A, Greshnova, I V, Zaslavsky, L G, Kotov, S V, Malkova, N A, Mishin, G N, Parshina, E V, Poverennova, I Ye, Prakhova, L N, Sivertseva, S A, Smagina, I V, Totolyan, N A, Trinitatsky, Yu V, Trushnikova, T N, Khabirov, F A, Chefranova, J Yu, Shchur, S G, Dudin, V A, Pokhabov, D V, Artemeva, A V, Eremeeva, A V, Linkova, Yu N, Zinkina-Orikhan, A V

“…To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg every 24 weeks…”
Get more information

Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA by Mazurov, V. I., Erdes, Sh. F., Gaydukova, I. Z., Dubinina, T. V., Pristrom, A. M., Kunder, E. V., Soroka, N. F., Kastanayan, A. A., Povarova, T. V., Zhugrova, E. S., Plaksina, T. V., Shesternya, P. A., Kropotina, T. V., Antipova, O. V., Smolyarchuk, E. A., Tsyupa, O. A., Abdulganieva, D. I., Lapshina, S. A., Krechikova, D. G., Gordeev, I. G., Nesmeyanova, O. B., Ilivanova, E. P., Strelkova, A. V., Tyrenko, V. V., Mikhailova, E. A., Eremeeva, A. V.

“…The article presents the results of the three-year use of netakimab (NTK) in patients with ankylosing spondylitis (AS) as part of the phase III…”
Get full text

T-bet syndrome-associated bronchial asthma phenotype by Sorokina, L. N., Mineev, V. N., Eremeeva, A. V., Nyoma, M. A.

“…We aimed to evaluate a significance of T-bet transcription factor in bronchial asthma (BA). A total of 102 patients with BA were examined. The control group…”
Get full text

Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study by Korotaeva, T. V., Mazurov, V. I., Lila, A. M., Gaydukova, I. Z., Bakulev, A. L., Samtsov, A. V., Khairutdinov, V. R., Zinkina-Orikhan, A. V., Sevastyanova, Yu. A., Eremeeva, A. V.

“…Netakimab is a humanized anti-interleukin-17А monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe…”
Get full text

EXPERIENCE OF OSMOTIC LAXATIVES (POLYETHYLENE GLYCOL 4000) USAGE IN TREATMENT OF CHRONIC CONSTIPATION IN CHILDREN by Eremeeva, A. V.

“…Aim: to assess clinical efficacy of polietilenglicol (macrogol) with molecular weight 4000 kDa in children with chronic constipation. Patients and methods:…”
Get full text

Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study by Korotaeva, T. V., Mazurov, V. I., Lila, A. M., Gaydukova, I. Z., Bakulev, A. L., Samtsov, A. V., Khairutdinov, V. R., Eremeeva, A. V., Morozova, M. A.

“…Netakimab (NTK) is a humanized anti-interleukin-17А (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis,…”
Get full text

Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR by Mazurov, V. I., Lila, A. M., Korolev, M. A., Prystrom, A. M., Kundzer, A. V., Soroka, N. F., Kastanayan, A. A., Povarova, T. V., Plaksina, T. V., Antipova, O. V., Krechikova, D. G., Smakotina, S. A., Tciupa, O. A., Puntus, E. V., Raskina, T. A., Shilova, L. N., Kropotina, T. V., Nesmeyanova, O. B., Popova, T. A., Vinogradova, I. B., Dokukina, E. A., Plotnikova, A. V., Pukhtinskaia, P. S., Zinkina-Orikhan, A. V., Linkova, Yu. N., Eremeeva, A. V., Lutckii, A. A., Nasonov, E. L.

“…Background . Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active…”
Get full text

Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR) by Mazurov, V. I., Korolev, M. A., Prystrom, A. M., Kunder, E. V., Soroka, N. F., Kastanayan, A. A., Povarova, T. V., Plaksina, T. V., Antipova, O. V., Kretchikova, D. G., Smakotina, S. A., Tciupa, O. A., Puntus, E. V., Raskina, T. A., Shilova, L. N., Kropotina, T. V., Nesmeyanova, O. B., Popova, T. A., Vinogradova, I. B., Linkova, Yu. N., Dokukina, E. A., Plotnikova, A. V., Pukhtinskaia, P. S., Zinkina-Orikhan, A. V., Eremeeva, A. V., Lutckii, A. A.

“…Levilimab is anti-interleukin-6 receptor (IL6R) monoclonal antibody. The article presents data obtained during 24 weeks of the SOLAR phase III study. Objective…”
Get full text

Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study by Mazurov, V. I., Zotkin, E. G., Gaydukova, I. Z., Ilivanova, E. P., Kropotina, T. V., Plaksina, T. V., Nesmeyanova, O. B., Soroka, N. F., Kunder, E. A., Dokukina, E. A., Linkova, Yu. N., Kravtsova, N. A., Pukhtinskaya, P. S., Eremeeva, A. V., Zinkina-Orikhan, A. V., Lutckii, A. A.

“…Levilimab (LVL) is a monoclonal antibody against the interleukin-6 receptor (IL6R). The article presents data obtained during 56 weeks of the AURORA phase II…”
Get full text

Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA by Mazurov, V. I., Erdes, Sh. F., Gaydukova, I. Z., Dubinina, T. V., Pristrom, A. M., Kunder, E. V., Soroka, N. F., Kastanayan, A. A., Povarova, T. V., Zhugrova, E. S., Plaksina, T. V., Shesternya, P. A., Kropotina, T. V., Antipova, O. V., Smolyarchuk, E. A., Tsyupa, O. A., Abdulganieva, D. I., Lapshina, S. A., Krechikova, D. G., Gordeev, I. G., Nesmeyanova, O. B., Ilivanova, E. P., Strelkova, A. V., Eremeeva, A. V., Zinkina-Orikhan, A. V.

“…Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic…”
Get full text

Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA by Mazurov, V. I., Gaydukova, I. Z., Erdes, Sh, Dubinina, T. V., Pristrom, A. M., Kunder, E. V., Soroka, N. F., Kastanayan, A. A., Povarova, T. V., Zhugrova, E. S., Plaksina, T. V., Shesternya, P. A., Kropotina, T. V., Antipova, O. V., Smolyarchuk, E. A., Tciupa, O. A., Abdulganieva, D. I., Lapshina, S. A., Krechikova, D. G., Gordeev, I. G., Nesmeyanova, O. B., Tyrenko, V. V., Ilivanova, E. P., Strelkova, A. V., Eremeeva, A. V.

“…Netakimab (NTK) is a humanized monoclonal antibody targeting interleukin-17A. Objective . The main objective of BCD-085-5/ASTERA study was to prove superiority…”
Get full text

Rheumatic manifestations of hypothyroidism by Teplova, L. V., Eremeeva, A. V., Baykova, O. A., Suvorova, N. A.

“…The rheumatic manifestations of endocrine diseases are well-known. The endocrine system has a complex effect on the structure and function of musculoskeletal…”
Get full text

Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3/AILAS) and extended (BCD-085-3ext/AILAS-II) phase II clinical trial by Erdes, Sh, Mazurov, V. I., Dubinina, T. V., Gaydukova, I. Z., Lapshina, S. A., Zonova, E. V., Krechikova, D. G., Plaksina, T. V., Reshetko, O. V., Smakotina, S. A., Shesternya, P. А., Gordeev, I. G., Makulova, T. G., Povarova, T. V., Raskina, T. A., Soroka, N. F., Pristrom, A. M., Kunder, E. V., Usacheva, Yu. V., Stukalina, E. Yu, Eremeeva, A. V., Chernyaeva, E. V., Ivanov, R. A.

“…The paper presents the results of a double-blind (BCD-085-3/AILAS) phase II clinical trial of the original interleukin 17A (IL17A) inhibitor BCD-085 prescribed…”
Get full text

EXPRESSION OF FoxP3 TRANSCRIPTION FACTOR IN BRONCHIAL ASTHMA by Eremeeva, A. V., Sorokina, L. N., Mineev, V. N., Lim, V. V., Nyoma, M. A., Trofimov, V. I.

“…Forty-two patients with allergic bronchial asthma (ABA) forty persons with non-allergic bronchial asthma (NABA), and 47 healthy controls were involved into the…”
Get full text

COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2 by Lila, A. M., Mazurov, V. I., Zonova, E. V., Nesmeyanova, O. B., Plaksina, T. V., Krechikova, D. G., Reshet’ko, O. V., Denisov, L. N., Gordeev, I. G., Pokrovskaya, T. G., Antipova, O. V., Kropotina, T. V., Povarova, T. V., Shesternya, P. A., Ushakova, E. N., Soroka, N. F., Kunder, E. V., Eremeeva, A. V., Chernyaeva, E. V., Ivanov, R. A., Pukhtinskaya, P. S.

“…The paper gives data on the clinical efficiency and safety profile of long-term use of the infliximab (INF) biosimilar BCD-055 versus the reference drug…”
Get full text

INTERACTION OF TRANSCRIPTION FACTORS PAX-5 AND STAT6 IN PATHOGENESIS OF ALLERGIC BRONCHIAL ASTHMA by Mineev, V. N., Sorokina, L. N., Nyoma, M. A., Eremeeva, A. V.

“…The aim of this work was to study an opportunity of coordinated expression of PAX-5 and STAT6 in bronchial asthma (BA) development. 35 healthy controls, 83…”
Get full text

Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies) by Karateev, D. E., Mazurov, V. I., Zonova, E. V., Nesmeyanova, O. B., Plaksina, T. V., Krechikova, D. G., Reshetko, O. V., Denisov, L. N., Gordeev, I. G., Pokrovskaya, T. G., Antipova, O. V., Kropotina, T. V., Povarova, T. V., Shesternya, P. A., Ushakova, E. N., Soroka, N. F., Pristrom, A. M., Eremeeva, A. V., Chernyaeva, E. V., Ivanov, R. A., Usacheva, U. V.

“…This article presents results from two clinical trials of infliximab biosimilar, BCD-055, including comparative data on the pharmacokinetics (PK), efficacy and…”
Get full text

THE RESULTS OF A PHASE III COMPARATIVE CLINICAL TRIAL OF RITUXIMAB (ACELLBIA® AND MABTHERA®) IN RHEUMATOID ARTHRITIS (THE BIORA STUDY) by Nasonov, E. L., Zonova, E. V., Ivanova, O. N., Knyazeva, L. A., Mazurov, V. I., Samigullina, R. R., Marusenko, I. M., Nesmeyanova, O. B., Plaksina, T. V., Sizikov, A. E., Krechikova, D. G., Petrochenkova, N. A., Shapovalova, Yu. S., Soroka, N. S., Pimanov, S. I., Pristrom, A. M., Kunder, E. V., Chernyaeva, E. V., Eremeeva, A. V., Ivanov, R.

“…The article considers the results of an international multicenter randomized clinical trial of the efficacy and safety of the brand-name drug rituximab…”
Get full text